These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 15076149)

  • 1. Is it the the renin-angiotensin-aldosterone blockade a comprehensive tool for the management of cardiovascular risk?
    Borghi C; Grassi G
    J Hypertens; 2004 Mar; 22(3):463-5. PubMed ID: 15076149
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hypertensiology 2007].
    Middeke M
    Dtsch Med Wochenschr; 2007 Jun; 132(25-26):1368-70. PubMed ID: 17570082
    [No Abstract]   [Full Text] [Related]  

  • 3. Defining the role of renin/angiotensin-targeted antihypertensive therapy in decreasing cardiovascular risk: evidence, guideline evolution, and questions to be resolved.
    Probstfield J
    J Fam Pract; 2009 Jun; 58(6 Suppl):S1-8. PubMed ID: 19508849
    [No Abstract]   [Full Text] [Related]  

  • 4. Complete renin-angiotensin-aldosterone system (RAAS) blockade in high-risk patients: recent insights from renin blockade studies.
    Rajagopalan S; Bakris GL; Abraham WT; Pitt B; Brook RD
    Hypertension; 2013 Sep; 62(3):444-9. PubMed ID: 23876474
    [No Abstract]   [Full Text] [Related]  

  • 5. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
    Chen SS; Seliger SL; Fried LF
    Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pleiotropic effects of drugs inhibiting the renin-angiotensin-aldosterone system.
    Jankowski P; Safar ME; Benetos A
    Curr Pharm Des; 2009; 15(5):571-84. PubMed ID: 19199982
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistant Hypertension On Treatment (ResHypOT): sequential nephron blockade compared to dual blockade of the renin-angiotensin-aldosterone system plus bisoprolol in the treatment of resistant arterial hypertension - study protocol for a randomized controlled trial.
    Cestário EDES; Fernandes LAB; Giollo-Júnior LT; Uyemura JRR; Matarucco CSS; Landim MIP; Cosenso-Martin LN; Tácito LHB; Moreno H; Vilela-Martin JF; Yugar-Toledo JC
    Trials; 2018 Feb; 19(1):101. PubMed ID: 29433578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Oral inhibitors of renin and their potential use as therapeutic agents in treating hypertension].
    Abassi Z; Armaly Z; Nakhoul F; Hoffman A
    Harefuah; 2008 Jun; 147(6):536-42, 573. PubMed ID: 18693632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
    Chrysant SG; Chrysant GS
    Curr Hypertens Rep; 2015 Jan; 17(1):511. PubMed ID: 25447989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Renin-angiotensin system blockade reduces cardiovascular mortality and morbidity attributable to arterial hypertension by primary and secondary prevention. The end of the road?].
    Coca A; Ruilope LM
    Med Clin (Barc); 2000 Jul; 115(5):178-80. PubMed ID: 10996874
    [No Abstract]   [Full Text] [Related]  

  • 11. Aliskiren: beyond blood pressure reduction.
    Riccioni G; Vitulano N; Zanasi A; Bellocci F; d'Orazio N
    Expert Opin Investig Drugs; 2010 Oct; 19(10):1265-74. PubMed ID: 20812878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Direct inhibition of renin: a physiological approach to treat hypertension and cardiovascular disease.
    Ram CV
    Future Cardiol; 2009 Sep; 5(5):453-65. PubMed ID: 19715410
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?
    Weber MA; Giles TD
    Rev Cardiovasc Med; 2006; 7(2):45-54. PubMed ID: 16915123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Therapeutic possibilities for the inhibition of the renin-angiotensin-aldosterone system].
    Abrahám G; Légrády P
    Orv Hetil; 2003 May; 144(18 Suppl 1):892-5. PubMed ID: 12785232
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arresting cardiovascular disease progression. Early treatment may counteract high risk.
    Ram CV; Vergne-Marini P
    Postgrad Med; 2004 Aug; 116(2):45-8. PubMed ID: 15323153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies blocking the renin-angiotensin-aldosterone system in the management of hypertension and related disorders.
    Krum H; Gilbert RE
    J Hypertens; 2007 Jan; 25(1):25-35. PubMed ID: 17143168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Blocking of the renin-angiotensin-aldosterone system in the study and treatment of arterial hypertension].
    Villarreal H
    Arch Inst Cardiol Mex; 1983; 53(1):1-3. PubMed ID: 6135394
    [No Abstract]   [Full Text] [Related]  

  • 18. [Renin and the heart].
    Ural D; Cetin M
    Turk Kardiyol Dern Ars; 2009 Oct; 37 Suppl 7():23-7. PubMed ID: 20019473
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?
    Volpe M; Danser AH; Menard J; Waeber B; Mueller DN; Maggioni AP; Ruilope LM
    J Hypertens; 2012 Apr; 30(4):647-54. PubMed ID: 22278139
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
    Horký K
    Vnitr Lek; 2007 Apr; 53(4):364-70. PubMed ID: 17578167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.